IP Library › Granted Patent US 12,241,093
Granted Patent B2
US 12,241,093 · App. 18/333,393 · Granted Mar 4, 2025

Biocatalysts for the preparation of hydroxy substituted carbamates

Inventors: Fabien Louis Cabirol (Dusseldorf, DE); Haibin Chen (Beijing, CN); Anupam Gohel (Bekasi, ID); Steven J. Collier (Concord, MA); Derek J. Smith (Singapore, SG); Birgit Kosjek (Westfield, NJ); Jacob Janey (New York, NY)
Assignee: Codexis, Inc.
C12N9/0006C12P13/00C12P13/001C12P13/02C12P41/002C12Y101/01184C12N15/70Y02P20/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,241,093
App. No.
18/333,393
Filed
Jun 12, 2023
Granted
Mar 4, 2025
Kind
B2
Art Unit
1652
USPC
435/190
Abstract

The present disclosure relates to engineered ketoreductase polypeptides for the preparation of hydroxyl substituted carbamate compounds, and polynucleotides, vectors, host cells, and methods of making and using the ketoreductase polypeptides.

Claims (10)

1. An engineered ketoreductase polypeptide capable of converting substrate compound (2), tert-butyl(1-oxo-1-phenylhex-5-yn-2-yl)carbamate, to product compound (1), tert-butyl(1-hydroxy-1-phenylhex-5-yn-2-yl)carbamate,

wherein the ketoreductase polypeptide comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO:4 and comprising a substitution at position 150 and/or 198, further comprising one or more residue differences as compared to SEQ ID NO:4 selected from X17R; X40R; X64V; X71P; X94P; X144V; X147I; X157C; X196M; and X206F.

2. The engineered ketoreductase polypeptide of claim 1 , wherein the amino acid sequence of said ketoreductase polypeptide further comprises one or more residue differences as compared to SEQ ID NO:4 selected from: X7S; X23V; X27L; X29G; X60I; X87L; X95M; X105G; X113I; X122A; X127R; X131S; X145L; X152G; X153G; X173L; X196M; X208R; X216R; X221S; X243S; X245I; X249F; X249G; and X249Y.

3. The engineered ketoreductase polypeptide of claim 1 , wherein the amino acid sequence of said ketoreductase polypeptide comprises X17R; X40R; X64V; X71P; X94P; X144V; X147I; X150Y; X157C; X196M; X198S and X206F as compared to SEQ ID NO:4.

4. The engineered ketoreductase polypeptide of claim 1 , wherein the ketoreductase polypeptide is capable of converting the substrate compound (2) to the product compound (1) with at least 10 fold the activity of the reference polypeptide of SEQ ID NO:4, wherein the amino acid sequence further comprises one or more residue differences as compared to SEQ ID NO:4 selected from: X60I; X95M; X96L; X96Y; X127RX145I; X152G; X153G; X195A; X195G; X199H; X216R, X245I, X245F; X249Y; and X249F.

5. The engineered ketoreductase polypeptide of claim 1 , wherein the ketoreductase polypeptide has increased thermal stability as compared to the reference polypeptide of SEQ ID NO:4 or 32.

6. The engineered ketoreductase polypeptide of claim 1 , wherein the ketoreductase polypeptide is capable of forming product syn-tert-butyl(1-hydroxy-1-phenylhex-5-yn-2-yl)carbamate compounds (1a) and (1c)

in diastereomeric excess of anti-tert-butyl(1-hydroxy-1-phenylhex-5-yn-2-yl)carbamate compounds (1b) and (1d).

7. The engineered ketoreductase polypeptide of claim 6 , wherein the amino acid sequence of the ketoreductase polypeptide further comprises or more residue differences as compared to SEQ ID NO:4 selected from: X87L; X96L/Y; X195A/G; X199H; and X249F.

8. The engineered ketoreductase polypeptide of claim 7 , wherein said ketoreductase polypeptide is capable of forming product compounds (1a) and (1c) in a diastereomeric ratio of at least 50 over compounds (1b) and (1d).

Assignments (1)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
Continuity (9)
Continuation 17084405 · Oct 29, 2020
Continuation 16284235 · Feb 25, 2019
Continuation 16126044 · Sep 10, 2018
Division 15711119 · Sep 21, 2017
Continuation 15211990 · Jul 15, 2016
Continuation 14825688 · Aug 13, 2015
Division 14357964
Provisional Application 61561665 · Nov 18, 2011
Related Publication 20240018489A1 · Jan 18, 2024
References Cited (98)
US 5538867A · Durliat et al. · 1996 [cited by applicant]
US 5559030A · Matsuyama et al. · 1996 [cited by applicant]
US 5700670A · Yamagishi et al. · 1997 [cited by applicant]
US 5846514A · Foster et al. · 1998 [cited by applicant]
US 5891685A · Yamagishi et al. · 1999 [cited by applicant]
US 6117679A · Stemmer · 2000 [cited by applicant]
US 6376246B1 · Crameri et al. · 2002 [cited by applicant]
US 6399339B1 · Wolbert et al. · 2002 [cited by applicant]
US 6495023B1 · Zeikus et al. · 2002 [cited by applicant]
US 6503921B2 · Naicker et al. · 2003 [cited by applicant]
US 6537746B2 · Arnold et al. · 2003 [cited by applicant]
US 6586182B1 · Patten et al. · 2003 [cited by applicant]
US 6613739B1 · Naicker et al. · 2003 [cited by applicant]
US 6645746B1 · Kizaki et al. · 2003 [cited by applicant]
US 6800477B2 · Patel et al. · 2004 [cited by applicant]
US 7705036B2 · Chou et al. · 2010 [cited by applicant]
US 9139819B2 · Cabirol et al. · 2015 [cited by applicant]
US 9422531B2 · Cabirol et al. · 2016 [cited by applicant]
US 9803178B2 · Cabirol et al. · 2017 [cited by applicant]
US 10100287B2 · Cabirol et al. · 2018 [cited by applicant]
US 10253303B2 · Cabirol et al. · 2019 [cited by applicant]
US 10851351B2 · Cabirol et al. · 2020 [cited by applicant]
US 20050095619A1 · Davis et al. · 2005 [cited by applicant]
US 20050153417A1 · Davis et al. · 2005 [cited by applicant]
US 20060195947A1 · Davis et al. · 2006 [cited by applicant]
US 20060286646A1 · Patel et al. · 2006 [cited by applicant]
US 20080220990A1 · Fox · 2008 [cited by applicant]
US 20080318295A1 · Ching et al. · 2008 [cited by applicant]
US 20090093031A1 · Liang et al. · 2009 [cited by applicant]
US 20090155863A1 · Liang et al. · 2009 [cited by applicant]
US 20090162909A1 · Campopiano et al. · 2009 [cited by applicant]
US 20090191605A1 · Liang et al. · 2009 [cited by applicant]
US 20090312196A1 · Colbeck et al. · 2009 [cited by applicant]
US 20100055751A1 · Voladri et al. · 2010 [cited by applicant]
US 20100062499A1 · Mundorff et al. · 2010 [cited by applicant]
WO 9522625A1 · 1995 [cited by applicant]
WO 970078A1 · 1997 [cited by applicant]
WO 9735966A1 · 1997 [cited by applicant]
WO 9827230A1 · 1998 [cited by applicant]
WO 0042651A1 · 2000 [cited by applicant]
WO 2000053731A2 · 2000 [cited by applicant]
WO 0140450A1 · 2001 [cited by applicant]
WO 0175767A2 · 2001 [cited by applicant]
WO 2005018579A2 · 2005 [cited by applicant]
WO 2005054491A1 · 2005 [cited by applicant]
WO 2008103248A1 · 2008 [cited by applicant]
WO 2009008908A2 · 2009 [cited by applicant]
WO 2009029554A2 · 2009 [cited by applicant]
WO 2009036404A2 · 2009 [cited by applicant]
WO 2009042984A1 · 2009 [cited by applicant]
WO 2009046153A1 · 2009 [cited by applicant]
WO 2009124166A1 · 2009 [cited by applicant]
WO 2009124167A1 · 2009 [cited by applicant]
WO 2010025085A1 · 2010 [cited by applicant]
WO 2010025238A2 · 2010 [cited by applicant]
WO 2010025287A2 · 2010 [cited by applicant]
WO 2010027710A2 · 2010 [cited by applicant]
WO 2011022548A2 · 2011 [cited by applicant]
WO 2011140219A1 · 2011 [cited by applicant]
Altschul, S.F., et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Res., 25(17):3389-3402 (1997). [cited by applicant]
Altschul, S., et al., “Basic local alignment search tool,” J. Mol. Biol., 215: 403-410 (1990). [cited by applicant]
Beaucage, S.L., et al., “Deoxynucleoside phosphoamidites-A new class of key intermediates for deoxypolynucleotide synthesis,” Tetrahedron Letters, 22(20):1859-62 (1981). [cited by applicant]
Black, M.E., et al., “Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy,” Proc Natl Acad Sci USA, 93:3525-3529 (1996). [cited by applicant]
Botstein, D., et al., “Strategies and applications of in vitro mutagenesis,” Science, 229(4719):1193-1201, 1985. [cited by applicant]
Broussy, S., et al., “Enantioselective, ketoreductase-based entry into pharmaceutical building blocks: ethanol as tunable nicotinamide reductant,” Org Lett., 11(2):305-308 [2009]. [cited by applicant]
Caldwell, R.C., et al., “Mutagenic PCR,” PCR Methods Appl., 3:S136-S140 (1994). [cited by applicant]
Carter, P., “Site-directed mutagenesis,” Biochem. J., 237:1-7 (1986). [cited by applicant]
Christians, F.C., et al., “Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling,” Nat. Biotechnol., 17:259-264 (1999). [cited by applicant]
Crameri, A., et al., “DNA shuffling of a family of genes from diverse species accelerates directed evolution”, Nature, 391:288-291 (1998). [cited by applicant]
Crameri, A., et al., “Improved green fluorescent protein by molecular evolution using DNA shuffling, ”Nat. Biotechnol., 14(3):315-319 (1996). [cited by applicant]
Crameri, A., et al., “Molecular evolution of an arsenate detoxification pathway by DNA shuffling,” Nat. Biotechnol., 15(5):436-438 (1997). [cited by applicant]
Dale, S.J., et al., “Oligonucleotide-directed random mutagenesis using the phosphorothioate method,” Methods Mol. Biol., 57:369-74 (1996). [cited by applicant]
Henikoff, S., et al., “Amino acid substitution matrices from protein blocks,” Proc. Natl. Acad. Sci. USA, 89:10915-10919 [1992]. [cited by applicant]
Hummel, W., et al., “Dehydrogenases for the synthesis of chiral compounds,” Eur. J. Biochem., 184:1-13 [1989]. [cited by applicant]
Igawa, Y., et al., “Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle,” Br J Pharmacol. 126(3):819-25 [1999]. [cited by applicant]
Igawa, Y., et al., “Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder,” Korean J Urol., 51:811-818 [2010]. [cited by applicant]
Koszelewski, D., et al., “Immobilization of omega-transaminases by encapsulation in a sol-gel/celite matrix,” Journal of Molecular Catalysis B: Enzymatic, 63: 39-44 (2010). [cited by applicant]
Kramer, B., et al., “Different base/base mismatches are corrected with different efficiencies by the methyl-directed DNA mismatch-repair system of [cited by applicant]
Ling, M., et al., “Approaches to DNA Mutagenesis:An Overview,” Anal. Biochem., 254:157-78 (1997). [cited by applicant]
Martin, A.R., et al., “Characterization of free and immobilized (S)-aminotransferase for acetophenone production,” Applied Microbiology and Biotechnology, 76(4): 843-851 (2007). [cited by applicant]
Mateo, C., et al., “Epoxy sepabeads: a novel epoxy support for stabilization of industrial enzymes via very intense multipoint covalent attachment,” Biotechnology Progress 18(3):629-34 (2002). [cited by applicant]
Matthes, H.W.D., et al., “Simultaneous rapid chemical synthesis of over one hundred oligonucleotides on a microscale,” EMBO J., 3(4):801-05 (1984). [cited by applicant]
Minshull, J., et al., “Protein evolution by molecular breeding,” Curr. Op. Chem. Biol., 3(3):284-290 (1999). [cited by applicant]
Needleman, S., et al., “A general method applicable to the search for similarities in the amino acid sequence of two proteins,” J. Mol. Biol. 48:443-453 (1970). [cited by applicant]
Pearson, W.R., “Improved tools for biological sequence comparison,” Proc. Nat'l. Acad. Sci. USA, 85:2444-2448 (1988). [cited by applicant]
Puigbo, P., et al., “Optimizer: a web server for optimizing the codon usage of DNA sequences,” Nucleic Acids Res., 35 (Web Server issue): W126-31 (2007). [cited by applicant]
Romanos, M.A., et al., “Foreign gene expression in yeast: a review,” Yeast 8:423-488 [1992]. [cited by applicant]
Santaniello, E., et al., “Chiral synthensis of a component of Amanita muscaria, (−)-4-Hydroxypyrrolidin-2-one, and assessment of its absolute configuration,” J. Chem. Res.(S), pp. 132-133 [1984]. [cited by applicant]
Smith, M., “In vitro mutagenesis,” Ann. Rev. Genet., 19:423-462 (1985). [cited by applicant]
Smith, T., et al., “Comparison of Biosequences,” Adv. Appl. Math, 2:482-489 (1981). [cited by applicant]
Stemmer, W., “DNA Shuffling by Random Fragmentation and Reassembly: In vitro Recombination for Molecular Evolution,” Proc. Natl. Acad. Sci. USA, 91:10747-10751 (1994). [cited by applicant]
Stemmer, W.P.C., “Rapid evolution of a protein in vitro by DNA shuffling”, Nature, 370:389-391 (1994). [cited by applicant]
Truppo, M.D., et al., “Development of an Improved Immobilized CAL-B for the Enzymatic Resolution of a Key Intermediate to Odanacatib,” Organic Process Research & Development, 15:1033-1035 (2011). [cited by applicant]
Wells, J.A., et al., “Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites,” Gene, 34:315-323 (1985). [cited by applicant]
Yi, S., et al., “Covalent immobilization of omega-transaminase from Vibrio fluvialis JS17 on chitosan beads,” Process Biochemistry 42(5): 895-898 (2007). [cited by applicant]
Zhang, J-H., et al., “Directed evolution of a fucosidase from a galactosidase by DNA shuffling and screening , ”Proc. Nat. Acad. Sci., U.S.A., 94:4504-4509 (1997). [cited by applicant]
Zhao, H., et al., “Molecular evolution by staggered extension process (StEP) in vitro recombination,” Nat. Biotechnol., 16:258-261 (1998). [cited by applicant]
Zhou, B., et al., “Stereochemical control of yeast reductions. 1. Asymmetric synthesis of L-carnitine,” J. Am. Chem. Soc., 105:5925-5926 [1983]. [cited by applicant]